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INTRODUCTION 
Dementia has become one of the most 
significant health challenges across the globe 
affecting about 35.6 million people and 
estimated to reach 115.4 million by 2050​1​. 
Dementia results in the deterioration of 
memory, thinking, behaviour and ability to 
complete adult activities​2​.  
 
Cognitive stimulation therapy (CST) is an 
overarching term that emcompasses all types 
of cognitive stimulating treatments. CST is 
typically provided in a group or individually as 
it creates an environment that is designed for 
a patient to have fun, learn or strengthen 
their relationships with others by preserving 
their cognitive skills for as long as possible. 
CST is based on implicit learning, stimulating 
language, and executive functioning​3​. CST 
includes activities focusing on orientation, 
reminiscence, new ideas, thoughts, and 
associations to promote continuity between 
treatment sessions​3​.  
 
Quality of life (QoL) is an established outcome 
measure of patients with dementia and is 
strongly influenced by an individual's 
environment and mood​4​. 
 
While there are many outcomes that can be 
examined with CST interventions, this 
systematic review focused on quality of life. 
METHODS 
A priori protocol was developed prior to 
conducting this systematic review for validity. 
The protocol is an outline which includes the 
PICO question, search strategies for each 
electronic database used, inclusion and 
exclusion criteria, and the search methodology 
 
 
 
(Appendix A). The protocol was created by five 
reviewers who collaborated and closely 
followed the outline to identify, appraise, and 
synthesize all relevant studies.  
 
Identification of Relevant Studies  
A systematic search was conducted to locate 
all relevant studies in February and March 
2020 using the following databases: 
PsychINFO Medical, CINAHL, ProQuest Health 
and Medical, and PubMed. All of these 
electronic databases were searched manually. 
 
Two reviewers independently searched each 
database and applied the inclusion/exclusion 
criteria to each study retrieved in the search. 
The inclusion criteria were first applied to the 
title and abstract of each study. However, if 
the inclusion criteria of the article was 
uncertain, the inclusion criteria were applied 
to the full text of the article to determine 
relevance. The flowchart summarizes the 
results of the systematic search and the 
application of the inclusion/exclusion criteria 
(Figure 1). Each reviewer created a list of the 
applicable  articles from their assigned l 
databases. These articles were then 
compared through a consensus process 
where discrepancies were resolved. A third 
reviewer was involved in this consensus if 
needed.  A final list of included articles across 
databases was produced when all authors 
came to a consensus.  
 
 
Inclusion and Exclusion Criteria 
To be included in this systematic review, the 
studies retrieved during the search had to 
meet the following inclusion criteria: (1) 
Adults 18+, (2) male and female, (3) mild to 
moderate dementia, (4) all types of dementia, 
(5) the intervention delivered was CST,  (5) 
outcomes for the study included quality of 
life, life satisfaction, or mental well-being, (6) 
studies in English, and (7)  
peer-reviewed scholarly articles (Table 5). 
 
Articles were excluded if they met the 
following criteria: (1) severe stages of 
dementia, (2) studies not in English, and (3) 
CST combined with another intervention 
where the results cannot be independently 
extracted (Table 5). 
 
Twenty articles fit the inclusion criteria and 11 
were previously appraised in existing 
systematic reviews ​11-19​. Therefore, the 11 
were not appraised by the reviewers; 
however, data from those articles were 
extracted to contribute to the results.  Nine 
articles remained to be appraised by the 
reviewers. 
Appraisal of Included Studies  
As depicted in the flowchart, 20 articles 
remained after inclusion/exclusion criteria, 
with 9 being appraised by the reviewers. 
Following the protocol, two reviewers 
independently appraised the quality of 
evidence in each article using predetermined 
criteria relevant for the study design. Two 
reviewers then compared their ratings of the 
quality of evidence to resolve discrepancies 
and reach consensus. A third reviewer was 
included to resolve discrepancies if needed. 
The quality of evidence table summarizes the 
quality of methodology ratings for each 
included study (Table 6). Two reviewers 
worked independently to summarize crucial 
information in each study to create a 
description table to reach a consensus, the 
two reviewers compared their independent 
study description tables. The final study 
description table included information 
regarding the data’s population, clinical and 
statistical significance, intervention, relevant 
 
 
 
outcomes, and results (Table 7). If there was 
no measure of clinical significance included in 
the data, the minimally detectable difference 
(MDD) was calculated.  
 
RESULTS 
A total of 723 articles were retrieved through 
the database searches, 20 of which met the 
predetermined inclusion criteria (Figure 1). 
Out of the 20 articles, 11 were previously 
appraised in existing systematic reviews ​11-19​, 
and therefore, were not appraised by the 
reviewers; however, data from the 11 articles 
were extracted to contribute to the results. 
Nine articles remained to be appraised by the 
reviewers. 
As noted in the study description table, the 
included studies used a mix of designs with a 
level of evidence ranging from I to III (Table 
6). Of the nine included articles, six were 
randomized control trials (RCT; data collected 
on an experimental group and control group 
that are randomly assigned), one was a 
single-case design (SCD; data collected at 
multiple points of the study on a single, small 
group of subjects), one was a 
quasi-experimental design (data collected on 
an experimental and control group that are 
not randomly assigned), and one was a 
one-group pretest/posttest design (data 
collected before and after an intervention on 
one group of subjects).  
Of the nine studies, four were classified on 
predetermined criteria​9​ as high quality 
(70%+)​20-23​, four were classified as moderate 
quality (40%-69%)​24-27​ and one was classified 
as low quality (>40%)​28​. Detailed information 
on the level and quality of evidence of each 
included study, is found in the Quality of 
Evidence Table (Table 6). Results of the nine 
appraised by the authors studies varied for 
the primary outcome (1) quality of life; four of 
the studies were found to be statistically 
significant for quality of life. 
Of the 11 articles that were previously 
appraised in existing systematic reviews, six 
were Level I ​1,​ ​3, 28-31​, one was Level II ​32​, and 
four were Level III ⁵​,​33-35​ Results of the 11 
studies varied for one primary outcome (1) 
quality of life; two of the 11 studies were 
found to be statistically significant for quality 
of life.  
When examining the articles for the results of 
the quality of life outcomes, the reviewers 
recognized that quality of life was referred to 
using variating terms such as mental-well 
being. Mental well-being was integrated 
under the quality of life outcome as both 
were defined in similar terms, resulting in 
quality of life being the umbrella term for the 
primary outcome. 
Quality of life 
The level of evidence for the quality of life 
outcome was mostly high; 12 out of 20 
studies were Level I,  1 out of 20 were Level II, 
and 7 out of 20 were Level III. The quality of 
evidence for this outcome was moderate as 
the majority of appraised articles indicated a 
moderate quality level; 3 studies were found 
to be of high quality, 5 were found to be of 
moderate quality, and 1 was found to be of 
low quality. The remaining studies quality of 
evidence could not be determined, given that 
they were not appraised by the reviewers. 
The degree of clinical significance for this 
outcome was determined to be low; only 6 
 
 
 
out of 20 studies were found to be clinically 
significant.  
PRACTICE RECOMMENDATIONS 
Out of the 20 articles that measured quality of 
life as the primary outcome, there was a 
preponderance of randomized control trials 
(level I) studies. By applying the GRADES 
classification system, reviewers determined a 
Grade A classification. Despite the Grade A 
classification, the burden/cost for this 
outcome demonstrated moderate quality. ​The 
potential burden and cost on families, 
caregivers, and individuals with dementia do 
not exceed the expected amount of benefits 
of this intervention. ​The clinical significance 
for QoL is also low however, this could be due 
to other reasons that took place during this 
study and how the study was performed. The 
quality of life outcome depicts a moderate 
quality. This means that further research is 
likely to have an impact on our confidence in 
the estimate of effect or may change the 
estimate, therefore results should be applied 
to patients cautiously. While study limitations 
exist, CST has potential to impact quality of 
life. 
CLINICAL IMPLICATIONS 
The 20 included studies within this systematic 
review evaluated the efficacy of Cognitive 
Stimulation Therapy (CST) on one primary 
outcome quality of life. Quality of life was 
classified as moderate quality using the 
modified GRADES system. Further research is 
warranted as the results demonstrated low  
 
CLINICAL TIPS 
Cognitive Stimulation Therapy (CST) is a 
moderate quality recommended intervention 
option for occupational therapy practitioners 
when addressing quality of life in persons with 
dementia. Additional research should be 
conducted to further determine the efficacy 
of CST in improving quality of life in persons 
with dementia. Additionally, occupational 
therapists would require specific training in 
the use of certain CST interventions in order 
to deliver such interventions with fidelity. 
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Appendix A​. “A Priori Protocol” 
 
Table 1.​ PICO Question 
 
PICO question 
P - 
 ​Persons with 
Dementia 
I - 
 ​Cognitive Stimulation 
C - 
 Any Therapy (not 
included in search) 
O – 
 Quality of Life 
 
 
Table 2​. Lists of Databases Searched  
 
Databases Included in SR Search Planned the Search 
  
Will conduct the Search 
Person 1 Person 2 Person 1 Person 2 
 PsychINFO (medical) Sondrea Brooke Jaid Riley 
 ​CINAHL  Jaid  Lynn  Sondrea Brooke 
 ProQuest (Health and Medical) Sondrea Brooke Jaid Lynn 
 ​PubMed  Sondrea Riley  Lynn Brooke 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3​. List of Search Terms 
 
  Construct 1 Construct 2 Limits (if 
any) 
Database Subject 
Headings 
Keywords Subject 
Headings 
Keywords   
PsychINFO 
(medical) 
 Dementia  
Alzheimer’s 
Disease 
“​Dementia” 
“Alzheimer*” 
 
Cognitive 
Rehabilitation 
Brain training  
 ​“cognitive 
stimulation” 
“brain 
training” 
“mental 
exercise” 
  
CINAHL Dementia 
Alzheimer’s 
Disease 
“Dementia” 
“Alzheimer’s” 
 None “cognitive 
stimulation” 
“cognitive 
rehabilitation” 
  
ProQuest 
(Health and 
Medical) 
 Dementia  
Alzheimer’s 
Disease  
 “​Dementia” 
“Alzheimer*” 
 None  ​“cognitive 
stimulation” 
“brain 
training” 
“mental 
exercise” 
  
PubMed  ​Dementia 
Alzheimer 
Disease 
“​Dementia” 
“Alzheimer*” 
 None “cognitive 
stimulation” 
“cognitive 
remediation” 
  
Note:  
PsychINFO→ ​is listed under PsychNet on our databases on the Gutman Library. APA thesaurus 
holds the subject headings  
ProQuest​→ use the proquest health and medical (there are different versions of this database), 
there is an advanced search option 
CINAHL​→ SH are searched under “MH Exact Subject Heading” (this is found under the drop down 
menu which has you select a field. 
Keywords:​ “TX all text” (same place where “MH Exact Subject Heading” is found) 
 
 
 
 
 
 
Table 4. ​Boolean Sentence for Each Database  
 
Database Name Boolean Sentence 
PsychINFO 
(medical) 
(​Dementia​ OR ​Alzheimer​ ​Disease​ OR “​Dementia​” OR “​Alzheimer​*”) AND 
(​cognitive​ ​rehabilitation​ OR ​brain​ ​training​ OR “​cognitive​ ​stimulation​” OR 
“​brain​ ​training​” OR “​mental​ ​exercise​”)  
CINAHL (​Dementia​ OR ​Alzheimer’s​ ​Disease​ OR “​Dementia​” OR “​Alzheimer’s​”) AND 
(“​cognitive​ ​stimulation​” OR “​cognitive​ ​rehabilitation​”) 
ProQuest (Health 
and Medical) 
 ​(​Dementia​ OR ​Alzheimer’s​ ​Disease​ OR “​Dementia​” OR “​Alzheimer​*”) AND 
(“​cognitive​ ​stimulation​” OR “​brain​ ​training​” OR “​mental​ ​exercise​”) 
 PubMed (​Dementia​ OR ​Alzheimer​ ​Disease​ OR “​Dementia​” OR “​Alzheimer​*”) AND 
(“​cognitive​ ​stimulation​” OR “​cognitive​ ​remediation​”) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.​ Inclusion and Exclusion Criteria  
 
Inclusion Criteria 
Population Intervention and 
Comparison 
Outcome Other 
- All Adults (18+) 
- Male and Female 
- Mild to moderate  
dementia (in 
reference to the 
stages or degree of 
cognitive decline) 
- All types of dementia 
(i.e: Alzheimer’s 
Disease, vascular 
dementia, etc.)  
- Cognitive stimulation 
- Cognitive stimulation 
therapy 
- Individual and group 
therapy  
- Cognitive 
rehabilitation  
- Cognitive training  
- Brain stimulation 
- Online programs 
- Mental exercises  
- Quality of life 
- Well-being  
- Life satisfaction 
- Studies in English  
- Defined controlled 
studies, group 
studies, SCDs  
- Peer reviewed 
scholarly articles 
- Intervention 
Exclusion Criteria 
Population Intervention and 
Comparison 
Outcome Other 
- Severe stages of 
dementia  
 - Interventions cannot 
be combined with 
another intervention 
(unless given 
distinguishable 
outcomes for each 
intervention)  
 - Studies not in 
English 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1​. ​Flow Chart 
 
 
 
 
 
 
 
 
Table 6.​ Quality and Level of Evidence Table 
 
  Quality Criteria     
Citation Type of 
design 
1 2 3 4 5 6 7 8 9 10 Quality 
Level 
Evidence 
Level 
(Allward et. al, 
2020) 
6 1 1 0 1 1 1 0 1 - - 6 
(high) 
3 
(Brueggen et al, 
2017)  
3 0 0 1 1 0 0 0 1 0 0 3 
(low) 
1 
(Kallio et. al, 2018)  3 1 1  1 1 1 0 0 1 0  0   6 
(mode
rate) 
 1 
(Kelly et. al, 2017) 6 1 1 0 0 1 0 1 1 -  -   5 
(mode
rate) 
 3 
(Middelstadt et. al, 
2016) 
3 1 1 1 1 1 1 0 1 0 0 7 
(high) 
1 
(Olakehinde et al, 
2019) 
6 1 1 0 0 1 1 1 1 - - 6 (6/8 
high) 
3 
(Orrell et. al 2017) 2 1 1 1 1 1 1 0 1 0 1 8 
(high) 
1 
(Orgeta et al., 2015) 2 1 1 1 1 0 1 0 0 0 1 6 
(mode
rate) 
1 
(Silva et al., 2017) 3 1 0 1 1 0 0 1 1 0 0 5 
(mode
rate) 
1 
 
 
 
 
 
 
Table 7​. Study Description Table 
 
 
 
Study Design 
Type 
Numbe
r of 
Criteria 
Met 
and 
Quality 
Level 
Popula
tion 
Interve
ntion(s) 
Compar
ison(s) 
N in 
each 
group 
Outco
me(s) 
Measur
ements 
Point 
estimat
es and 
directio
n of 
differe
nces  
sd, se, 
or CI 
for the 
estimat
e  
Statisti
cal 
signific
ance  
Clinical 
signific
ance  
(Allwar
d et. al, 
2020) 
Quasi-
experi
mental 
6 (mod) Diagno
sis: 
Mild to 
modera
te 
Demen
tia/Alzh
eimer’s 
 
Age: 
63-97 
years 
of age 
 
Gender
: 
Male 
and 
Female  
CST n/a n=60 Mental 
well-be
ing 
SWEM
WBS 
(higher 
score 
indicat
es state 
of 
positive 
mental 
well-be
ing) 
Pre-Tes
t 
M=-24.
89 
 
 
Post-te
st 
M=-25.
87 
Pre-Tes
t 
SD=-4.2
6 
 
 
Post-te
st 
SD=-5.2
0 
Pre and 
Post-Te
st 
differe
nce: 
 p = 
-0.085 
MDD= 
Not 
C.S. 
(Bruegg
en et 
al., 
2017) 
RCT 3(low) Diagno
sis: 
Mild to 
modera
te 
dement
ia (or 
mixed)  
  
Age:  
M=70.0
6 
 
Gender
: 
Not 
specifie
d 
Cognitiv
e 
Rehabili
tation 
progra
m 
based 
on the 
CORDIA
L 
progra
m 
present
ed by 
Werhei
d and 
Thone–
Otto in 
2010  
 
Control 
group 
received 
standar
dized 
Cognitiv
e 
training 
in the 
form of 
homew
ork 
perform
ed 
indepe 
n=16 QoL DEMQo
L 
(1-4 
Likert 
Scale, 
higher 
scores 
indicati
ng 
better 
HQRL) 
Baselin
e  
EG: 
M=30.0
0 
CG: 
M=34.7
5 
Baselin
e to 
Post-Int
erventi
on  
 
EG: 
MD= 
3.1 
 
Baselin
e  
 
EG: 
SD=7.7
6 
 
CG:  
SD= 
6.16 
Baselin
e to 
Post-int
erventi
on  
EG: 
SD=5.7
9 
 
 
Baselin
e to 
post 
interve
ntion 
differe
nces 
and 
interact
ion 
effect: 
p= 
0.013 
MDD= 
C.S. 
 
 
 
CG: 
MD=-4.
4 
CG:  
SD= 
5.40 
(Capot
oso, et 
al, 
2016) 
RCT Apprais
ed by: 
(Lobbia 
et al. 
2019) 
Diagno
sis: 
Mild to 
modera
te 
dement
ia 
 
Age:  
EG: 
M=88.2
5 
CG: 
M=86.5
2 
 
Gender
: 
Not 
specifie
d 
CST-IT Active 
control 
group 
n=39 QoL QoL-AD 
(score:
13-52, 
higher 
score 
equals 
better 
functio
ning) 
Pre-Tes
t 
EG: 
M= 
22.10  
  
CG: 
M=19.3
2 
 
Post-Te
st  
EG: 
M=23.3
5  
 
 
 
CG: 
M= 
19.37 
Pre-Tes
t​: 
EG: 
SD= 
8.17 
 
CG: 
SD=7.2
3 
 
Post-Te
st​:  
EG: 
SD= 
8.10 
 
 
CG: 
SD=6.7
8 
Betwee
n 
subject
s: 
p= 0.17 
 
Pre vs 
Post 
test 
repeate
d 
measur
es: 
p=0.05 
MDD= 
Not 
C.S. 
(Davis, 
et al, 
2001) 
RCT Apprais
ed by: 
(Cooper 
et al., 
2012), 
(Fukush
ima et 
al., 
2016), 
(Olazar
an et 
al., 
2010) 
Diagno
sis: 
Probabl
e 
Alzhei
mer’s 
Disease 
 
Age: 
EG  
M= 
68.67  
CG  
M= 
72.56  
 
Gender
: 
Male 
and 
Female 
Cognitiv
e 
interve
ntion 
Placebo 
Conditio
n (Mock 
Interven
tion) 
n=37 QoL QLA-P 
(scale 
0-50, 
higher 
scores 
reflect 
higher 
QoL) 
Time 1  
EG: 
M=269.
17  
 
CG: 
M=269.
94  
 
 
Time 2 
EG: 
M=244.
41 
 
CG: 
M=269.
71  
  
 
Time 1  
EG: 
SD=51.
28 
 
CG: 
SD=67.
94 
 
 
Time 2 
EG: 
SD=62.
11 
 
CG: 
SD=51.
64 
Group 
x Time 
F Ratio: 
p= 2.10 
MDD= 
Not 
C.S. 
(Kallio 
et al, 
2018) 
Single 
Blind 
RCT 
6 (Mod) Diagno
sis: 
Establis
hed 
dement
ia 
 
Cognitiv
e 
training 
Routine 
day care 
n= 
147 
QoL HQRL 
instrum
ent 
(15D) 
(0-1 
scale, a 
higher 
HQRL 
instrum
ent 
(15D):  
 
Baselin
e 
HQRL 
instrum
ent 
(15D) 
 
Baselin
e 
HQRL 
instrum
ent 
(15): 
Change 
over 
time 
MDD 
cannot 
be 
calculat
ed 
 
 
 
Age: 
65 
years+ 
 
Gender
: 
Not 
specifie
d 
score 
indicat
es a 
higher 
HRQL) 
 
EG: 
M= 
0.740 
 
CG: 
M= 
0.741 
 
 
 
EG: 
SD= 
0.086 
 
CG: 
SD=0.0
83 
Baselin
e to 3 
months
: 
EG: 
CI= 
-0.058 
to 
-0.021 
  
CG: 
CI= 
-0.056 
to 
-0.018 
 
No 
reporte
d 
change
s 
baselin
e to 9 
months 
EG  p= 
0.61 
 
(Kelly, 
et. al., 
2017) 
Single-
case 
design 
 5 
(Mod) 
 
Diagno
sis: 
People 
with 
dement
ia 
 
Age: 
53-86 
 
Gender
: 
Male 
and 
Female 
 
CST N/A n=20 QoL QoL-AD 
(score:
13-52, 
higher 
score 
equals 
better 
functio
ning) 
Baselin
e​ M= 
35.25 
  
 
Post-CS
T​ M= 
35.80 
Baselin
e 
SD= 
7.89 
 
Post-CS
T 
SD=5.7
8 
 QoL 
self-rat
ed 
p = 
0.763 
 
MDD = 
Not 
C.S. 
(Kim, et 
al, 
2016 
RCT Apprais
ed by: 
(Fukusi
ma et 
Diagno
sis: 
patient
s with 
Alzhei
Cognitiv
e 
Progra
mming 
Control 
Group 
n= 53 QoL QoL-AD 
(score:
13-52, 
higher 
score 
Baselin
e 
EG: 
M=28.2
5  
Baselin
e 
EG: 
SD= 
6.72 
Baselin
e​ for 
EG and 
CG 
MDD= 
Not 
C.S. 
 
 
 
al, 
2016) 
 
mer’s 
Disease 
 
Age: 
M= 
48.48 ​+ 
1.45 
 
Gender
: 
Wome
n 
equals 
better 
functio
ning) 
  
 
CG: 
M= 
27.35  
 
6 
months 
EG: 
M= 
27.84 
 
CG: 
M= 
27.12 
 
Change 
from 
Baselin
e to 6 
months 
 
EG: 
M=0.40 
 
CG: 
M=0.23 
 
 
CG: 
SD= 
7.23 
 
6 
months 
EG: 
SD= 
5.30 
 
CG: 
SD= 
6.50 
 
Change 
from 
Baselin
e to 6 
months 
EG: 
SD=0.7
6 
 
CG: 
SD=0.7
3 
 
p= 
0.65* 
 
 
EG and 
CG 
change: 
p=0.60
* 
(Lin, et 
al, 
2018) 
 
Quasi-
experi
mental 
Design 
Apprais
ed by: 
(Chao 
et al., 
2020) 
Diagno
sis: 
People 
with 
dement
ia 
 
Age: 
M=79.5 
± 7.7. 
 
Gender
: 
Male 
and 
Female 
 
CST RT and 
control 
group 
n= 
105 
QoL QoL-AD 
(score:
13-52, 
higher 
score 
equals 
better 
functio
ning) 
RT: 
M 
=26.7  
  
CST:  
M= 
22.5  
 
CG: 
 M= 
23.0  
RT: 
SD= 4.5 
 
 
CST: 
SD= 4.6 
 
 
CG 
SD= 4.9 
Short 
term 
effects 
betwee
n pre 
and 
post 
test 
scores 
among 
the 
groups 
on QoL: 
p<0.00
1 
MDD = 
C.S.  
(Middel
stadt et 
al, 
2016) 
 
RCT 7 (High) Diagno
sis: 
mild to 
modera
te 
dement
ia  
CST CG: 
routine 
care at 
nursing 
facility 
n= 71 QoL QoL-AD 
(score:
13-52, 
higher 
score 
equals 
better 
 
 
EG:  
M=34.1
7  
 
 
CG: 
 
 
EG: 
SD=4.7
7 
 
 
CG: 
QoL-AD
:  
EG 
p=0.65 
Moder
ate 
effect 
size 
(0.11) = 
C.S. 
 
 
 
  
Age: 
EG: 
M=: 
86.25 
CG: 
M=86.4
9 
 
Gender
: 
Male 
and 
Female 
 
 
functio
ning)  
M=33.6
6 
SD= 
4.49 
(Olakeh
inde et 
al, 
2019) 
 
 One 
group. 
Pre/Po
st test  
 6 
(high) 
Diagno
sis:  
Demen
tia. 
 
Age  
65+  
 
Gender
: 
Male 
and 
Female 
CST  N/A n=9 QoL 
(4 sub) 
categor
ies: 
physica
l, 
psycho
social, 
social, 
and 
environ
mental) 
WHOQ
oL-Bref
(Scores 
scaled 
in a 
positive 
directio
n, 
higher 
scores 
indicat
es 
higher 
QoL) 
WHOQ
oL-Bref
:  
 
Median
: 
  
Physica
l​: 
Pre: 
10.3  
 
 
 
Post: 
14.9  
 
 
 
Psycho
social​: 
Pre: 
10.7  
 
 
Post: 
12.7 
 
 
Social​: 
Pre: 
14.0 
 
 
Post: 
16.0 
 
 
Environ
ment 
Pre: 
10.0 
 
 
WHOQ
oL-Bref
: 
 
IQR: 
 
 
Physica
l​: 
Pre: 
(9.4–12
.9) 
 
 
Post: 
(12.3–1
6.0) 
 
 
Psycho
social​: 
Pre: 
(10.0–1
2.7) 
 
Post: 
(14.0-1
4.7) 
 
Social​: 
Pre 
(12.0-1
6.7) 
 
Post: 
(13.7-1
7.0) 
 
Environ
ment: 
Pre: 
(9.5-12.
0) 
 
 
 
 
 
 
 
Physica
l​: 
p<0.05 
r=0.587 
 
 
 
 
 
 
 
 
Psycho
social​: 
p<0.05 
r=0.596 
  
 
 
 
 
 
Social​: 
p>0.05 
r=0.232 
 
 
 
 
 
 
Environ
ment​: 
p<0.01 
r=0.630 
**Physi
cal, 
Psycho
Article 
stated: 
MD = 
C.S 
 
 
 
Post: 
13.5 
  
 
Post: 
(11.5-1
4.8) 
social, 
and 
environ
ment 
ARE 
statistic
ally 
signific
ant. 
Social 
is NOT 
statistic
ally 
signific
ant  
 
(Orrell 
et. al, 
2017) 
 
RCT 8 (high) Diagno
sis: 
Mild to 
Moder
ate 
Demen
tia 
 
Age: 
Not 
specifie
d  
 
Gender
: 
Female 
 
CST Treatme
nt as 
usual 
(TAU) 
n= 
356 
QoL QoL-AD 
(score:
13-52, 
higher 
score 
equals 
better 
functio
ning)  
 
 
  
 
 
DEMQo
L 
(1-4 
Likert 
Scale, 
higher 
scores 
indicati
ng 
better 
HQRL) 
QoL-AD 
13 
week 
MD= 
-0.14 
 
 
26 
week 
MD= 
-0.02 
 
 
 
DEMQo
L 
13 
week 
MD= 
-0.33 
 
 
26 
week 
MD= 
0.31 
QoL-AD 
13 
week 
CI= 
(−1.12-
0.84)  
 
26 
week 
CI= 
(−1.04-
1.00 ) 
 
 
DEMQo
L 
13 
week 
CI= 
(-2.31-
1.65) 
 
26 
week  
CI= 
(-1.62-
2.22) 
QoL-AD 
13 
week 
p= 0.78 
 
 
 
26 
week 
p= 0.97 
  
  
 
 
DEMQo
L 
13 
week 
p= 0.74 
QoL-AD 
MDD= 
Not C.S  
 
 
 
 
 
 
 
 
 
 
 
DEMQo
L 
MDD=  
Not 
C.S. 
(Orgeta 
et al., 
2015) 
RCT 6 (mod) Diagno
sis: 
mild to 
modera
te 
dement
ia  
 
Age: 
EG: 
M= 
78.40 
iCST 
(Individ
ual 
stimulat
ion 
therapy
) 
Control 
group:r
eceived 
treatme
nt as 
usual 
(TAU) 
n= 
356 
QoL QoL-AD 
(score:
13-52, 
higher 
score 
equals 
better 
QoL)  
QoL-AD 
Baselin
e​: 
EG: 
M=32.8
8 
 
CG: 
M=33.0
9 
 
QoL-AD 
Baselin
e​: 
EG: 
SD=6.8
3 
 
CG: 
SD=6.2
2 
 
QoL-AD 
 
 
 
 
 
 
 
 
 
 
Small 
effect 
size= 
Not 
C.S. 
 
 
 
CG: 
M= 
78.00 
 
Gender
:  
not 
specifie
d  
Week 
13 
EG: 
M=37.9
0 
 
 
 
 
CG: 
M=38.0
9 
 
 
 
 
 
 
 
 
 
Week 
26  
EG: 
M= 
37.86 
 
CG: 
M=37.7
1 
Week 
13 
EG: 
SD= 
5.52 
CI=-1.1
2 to 
0.84 
 
CG: 
SD=5.6
3 
Week 
13  
EG and 
CG 
groups: 
CI:-1.12
-0.84 
 
 
Week 
26 
EG: 
SD=5.1
3 
 
CG: 
SD=5.9
1 
 
 
Week 
26​ EG 
and CG 
groups: 
CI= 
-1.04 to 
1.00 
 
 
Week 
13 
Compa
rison of 
EG and 
CG 
groups: 
p= 0.78 
  
 
 
 
 
 
 
 
 
 
 
 
 
Week 
26 
Compa
rison of 
EG and 
CG 
groups: 
p= 0.97 
 
 
 
(Paddic
k, et al, 
2017) 
Pre 
and 
post 
interve
ntion 
Apprais
ed by: 
(Chao 
et a.l, 
2020) 
and 
(Lobbia 
et al, 
2019) 
Diagno
sis: 
Mild to 
Moder
ate 
Demen
tia  
 
Age: 
65+ 
 
Gender
: 
Not 
specifie
d  
 
CST N/A n=34 QoL WHOQ
OL-Bref 
(Scores 
scaled 
in a 
positive 
directio
n, 
higher 
scores 
indicat
es 
higher 
QoL) 
WHOQ
OL-Bref
: 
Median
s: 
Physica
l ​Pre: 
11.4 
 
 
 
Immedi
ate 
Post: 
13.1 
 
 
Eight-w
eek 
Post: 
13.7 
  
 
Psychol
ogical  
Pre:  
14.0 
 
 
 
Immedi
ate 
Post: 
14.7 
 
 
Eight-w
eek 
Post:  
15.0  
 
 
Social 
Pre: 
16 
 
Immedi
ate 
Post: 
16.0 
 
 
Eight-w
eek 
WHOQ
OL-Bref
: 
IQR: 
 
Physica
l 
Pre: 
9.7-14.
3 
 
 
Immedi
ate 
Post: 
10.3-14
.9 
 
Eight-w
eek 
pst: 
11.6-14
.6 
 
 
Psychol
ogical 
Pre: 
12.7-15
.3 
 
 
Immedi
ate 
Post: 
12.7-16
.0 
 
Eight-w
eek 
Post: 
13.5-16
.0 
 
Social  
Pre: 
12.0-8.
0 
Immedi
at 
Post:  
12.0-20
.0 
 
 
 
 
 
 
Physica
l 
Change 
betwee
n pre 
and  
 
immedi
ate 
post: 
p=0.04
1 
 
 
 
 
 
 
 
Psychol
ogical 
Change 
betwee
n pre 
and  
 
Immedi
ate 
post: 
p= 
0.531 
 
 
 
 
 
 
 
Social 
Change 
betwee
n pre 
and 
immedi
ate 
post: 
p=0.82
9 
 
 
Mediu
m 
effect 
size 
(0.6) = 
C.S. 
 
 
 
Post: 
16.0 
Environ
mental 
Pre:  
14.5 
 
 
 
Immedi
ate 
Post:  
14.5 
 
 
Eight-w
eek 
Post: 
13.5 
 
Eight-w
eek 
Post: 
16.0-18
.0 
Environ
mental 
Pre: 
12.5-16
.0 
 
 
Immedi
atePost
: 
13.0-16
.5 
 
Eight-w
eek 
Post: 
12.5-15
.0 
 
 
 
Environ
ment 
Change 
betwee
n pre 
and  
 
immedi
ate 
post: 
p=0.19
4 
(Piras, 
et al, 
2017)  
Single 
blind 
RCT 
Apprais
ed by: 
(Chao 
et al., 
2020) 
Diagno
sis: 
Mild to 
modera
te 
Vascula
r 
Demen
tia 
 
Age: 
EG 
M=83.8 
CG 
M=85.4 
 
Gender
: 
Male 
and 
Female 
CST-IT Control 
group 
n= 35 QoL QoL-AD 
(score:
13-52, 
higher 
score 
indicat
es a 
higher 
QoL) 
Pre-tes
t 
EG: 
M=25.0
5  
  
CG: 
M= 
28.43 
 
Post-te
st​ EG: 
M=27.3
5  
 
CG: 
M= 
28.00 
Pre-tes
t 
EG: 
SD= 
9.78 
 
CG: 
SD=7.8
2 
 
Post-te
st 
EG: 
SD= 
9.41 
 
CG: 
SD= 
6.87 
EG vs 
CG: 
p= 0.27 
MDD = 
Not 
C.S. 
(Silva, 
et al, 
2017) 
Single 
blind 
RCT 
Numbe
r of 
criteria 
met: 5 
 
Modera
te Level 
Quality  
 
Diagno
sis: 
Alzhei
mer’s 
Disease  
 
Age: 
60-80 
years 
old 
SenseC
am 
 
Memo+ 
 
Persona
l Diary 
 n= 67 QoL WHOQ
OL-OLD 
(28 
items 
on a 5 
point 
scale 
coverin
g 7 
WHOQ
OL-OLD 
: 
Sensec
am: 
Visit 1: 
M=109.
33 
 
WHOQ
OL-OLD
: 
Sensec
am​Visit 
1: 
SD=15.
64 
 
WHOQ
OL_OL
D: 
Main 
effect 
of EG:  
p< 0.01 
WHOQ
OL-OLD 
Sensec
am: 
MDD = 
C.S. 
 
 
 
 
 
 
 
Gender
: not 
specifie
d 
 
domain
s, 
higher 
scores 
indicat
e 
higher 
QoL)  
Visit 2: 
M=116.
47  
 
Visit 3: 
M=110.
00  
 
Memo+
: 
Visit 1: 
M=103.
75  
 
Visit 2: 
M=107.
19  
 
Visit 3: 
M=103.
38  
 
Diary: 
Visit 1: 
M=100.
27 
 
Visit 2: 
M=99.2
0 
 
Visit 3: 
M=91.2
7 
 
GDS: 
Sensec
am: 
Visit 1: 
M=12.6
4  
 
Visit 2: 
M=6.79  
 
Visit 3: 
M=7.57  
 
Memo+ 
Visit 1: 
M=11.4
4  
 
Visit 2: 
Visit 2: 
SD=12.
71 
 
Visit 3: 
SD=16.
73 
 
Memo+ 
 
Visit 1: 
SD=12.
86 
 
Visit 2: 
SD=11.
26 
 
Visit 3: 
SD=10. 
28 
 
Diary: 
Visit 1: 
SD=0.3
4 
 
Visit 2: 
SD=9.6
6 
 
Visit 3: 
SD=24.
67 
 
GDS: 
Sensec
am​Visit 
1: 
SD=6.2
5 
 
Visit 2: 
SD=3.6
6 
Visit 3: 
SD=4.0
3 
Memo+ 
Visit 1: 
SD=4.6
2 
 
Visit 2: 
 
 
 
 
 
 
 
 
Memo+
: 
MDD = 
C.S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GDS 
Sensec
am: 
MDD = 
C.S. 
 
 
 
 
 
 
 
 
 
Memo+
: 
MDD = 
Not 
C.S. 
 
 
 
 
M=10.3
1 
 
Visit 3: 
M=11.0
6  
 
Diary: 
Visit 1: 
M=13.0
0  
 
Visit 2: 
M=13.4
0  
 
Visit 3: 
M=14.6
0 
SD=5.1
2 
 
Visit 3: 
SD=4.5
0 
 
Diary: 
Visit 1: 
SD=5.2
9 
 
Visit 2: 
SD=5.2
2 
 
Visit 3: 
SD=5.1
2  
(Specto
r, et al, 
2003) 
Single-
blind 
RCT 
Apprais
ed by: 
(Aguirr
e et al., 
2013), 
(Cooper 
et al., 
2012), 
(Kurz et 
al., 
2011), 
(Yuill & 
Hollice, 
2011), 
(Chao 
et al., 
2020), 
and 
(Lobbia 
et al., 
2019) 
Diagno
sis: 
people 
with 
dement
ia 
  
Age: 
M= 
85.3  
 
Gender
: 
Male 
and 
Female 
CS Control 
Group 
n= 
201 
QoL QoL-AD 
(score:
13-52, 
higher 
score 
indicat
es a 
higher 
QoL)  
Baselin
e 
EG: 
M=33.2  
 
CG: 
M=33.3  
 
Follow-
up 
EG: 
MD: 
1.3 
 
CG: 
MD: 
-0.8 
Baselin
e  
EG: 
SD: 5.9 
 
CG 
SD: 5.7 
 
Follow-
up 
EG: 
SD: 5.1 
 
CG: 
SD: 5.6 
 
Group 
differe
nce-cha
nge 
from 
baselin
e:  
CI: 0.9 
to 3.18 
Betwee
n group 
differe
nces 
p=0.02
8 
MDD  = 
Not 
C.S. 
(Stewar
t, et al, 
2017) 
Observ
ational, 
descrip
tive 
pre-tes
t/post-
test 
study 
design 
Apprais
ed by: 
(Lobbia 
et al., 
2019) 
Diagno
sis: 
people 
with 
dement
ia 
 
Age: 
CST N/A n= 40 QoL QoL-AD 
(score:
13-52, 
higher 
score 
indicat
es a 
higher 
QoL) 
Baselin
e 
M=34.9
8 
 
Pre-tes
t 
M=34.9
8 
Baselin
e 
SD=6.2
0 
 
Pre-tes
t 
SD=6.2
0 
Compa
ring pre 
and 
post 
test 
scores: 
p= 0.09 
MDD = 
Not 
C.S. 
 
 
 
M=78.0
8 
 
Gender
: 
Male 
and 
Female 
 
Post-te
st 
M=36.1
6  
 
Post-te
st 
SD=5.8
0 
(Streat
er, et 
al, 
2016)  
Observ
ational 
study 
design 
Apprais
ed by: 
(Chao 
et al., 
2020) 
Diagno
sis: 
Alzhei
mer’s 
and 
Demen
tia 
 
Age: 
M= 
80.4 ±
 7.2  
 
Gender
: 
Male 
and 
Female 
CST N/A n=89 QoL QoL-AD 
(score:
13-52, 
higher 
score 
indicat
es a 
higher 
QoL) 
Baselin
e 
M=36.5
3  
  
Follow-
up 1 
M=35.6
5  
 
Baselin
e 2 
M=36.3
4 
 
Follow-
up 2 
M=36.7
3 
Baselin
e​ SD= 
7.32 
 
 
Follow-
up1 
SD= 
8.37 
 
Baselin
e 2 
SD= 
7.64 
 
Follow-
up 2 
SD= 
5.30 
 
 
 
 
 
Baselin
e 1 
CI= 
-0.64, 
2.40 
 
Baselin
e 2 
CI= 
-2.21, 
1.43 
Interac
tion 
betwee
n 
baselin
e and 
follow-
up 1: 
p=0.13 
 
 
Interac
tion 
betwee
n 
baselin
e 2 and 
follow-
up 2: 
p=0.34 
Follow 
Up 1: 
MDD= 
Not 
C.S. 
 
Follow 
up 2: 
MDD = 
Not 
C.S. 
(Woods
, et al, 
2006)  
RCT Apprais
ed by: 
Diagno
sis: 
Moder
ate to 
CST Control 
group 
n=201 QoL QoL-AD 
(score:
13-52, 
higher 
EG:  
MD=1.
3 
 
EG: 
SD=5.1 
 
 
Had a 
signific
ant 
positive 
MDD= 
Not 
C.S. 
 
 
 
(Yuill & 
Hollice, 
2011), 
(Chao 
et al., 
2020), 
and 
(Lobbia, 
2019) 
severe 
dement
ia 
 
Age: 
M=85.3  
 
Gender
: 
Male 
and 
Female 
score 
indicat
es a 
higher 
QoL) 
CG: 
MD=-0.
8 
CG: 
SD=5.6 
effect 
on total 
QoL-AD 
score 
(F = 6.
87, 
p < 0.
05) 
(Yaman
aka, et 
al, 
2013)  
Single-
blind 
RCT 
Apprais
ed by: 
(Lobbia 
et al. 
2019) 
Diagno
sis: 
mild to 
modera
te 
dement
ia 
  
Age:  
M= 
83.91 
  
Gender
: 
Male 
and 
Female 
CST Control 
group 
n= 56 QoL QoL-AD 
(score:
13-52, 
higher 
score 
indicat
es a 
higher 
QoL) 
Pre-Tes
t  
EG: 
M= 
28.40  
 
CG: 
M=28.6
2 
 
Post-Te
st 
EG: 
M= 
28.59 
 
 
CG: 
M=28.1
9 
Pre-tes
t  
EG: 
SE= 
1.19 
 
CG: 
SE= 
1.17 
 
 
Post-te
st  
EG: 
SE= 
1.19 
 
 
CG: 
SE=1.2
0 
Betwee
n group 
x 
within 
group 
interact
ion: 
p= 
0.673 
MDD = 
Not 
C.S.  
M= mean, MD= mean difference, SE= standard error, n= total number, IQR= interquartile range, CST= cognitive stimulation therapy, CS= 
cognitive stimulation, RT= reminiscence therapy, QoL= quality of life, CI= confidence interval, EG= experimental (intervention group), CG= 
control group, MDD= minimal detectable change, C.S.= clinically significance, SWEMWBS=Short Warwick Edinburgh Mental Well-Being Scale, 
DEMQoL=Dimensions of Quality of Life Questionnaire, QoL-AD=Quality of Life-Alzheimer’s Disease Scale, QLA-P=The Quality of Life 
Assessment-- Patient, HQRL=Dimensional Health Related Quality of Life Instrument, WHOQoL-Bref=World Health Organization Quality of Life 
Assessment- Bref Version, WHOQoL-OLD=World Health Organization Quality of Life Assessment-OLD Version, GDS-30=Geriatric Depression 
Scale-30 
 
 
